STAAR Surgical Q3 2026: Revenue Beat Masks a Margin Squeeze
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Gross margin collapsed to 70.9% on ERP-related production costs, freight and China tariffs, which is why revenue topped estimates while earnings missed expectations. Management says the margin squeeze starts easing in Q4, and all China-bound lens production has moved to Switzerland to sidestep tariffs.
Continue ReadingShow less
STAAR Surgical reported Q3 2026 revenue of $83.41 million, ahead of analyst consensus. That topline win came with a significant catch: gross margin fell to 70.9% from 82.2% in the year-ago period, leaving GAAP EPS at $0.11 and missing expectations.
Three cost pressures converged to squeeze the margin. A second-quarter ERP system rollout left manufacturing running at reduced volumes, lifting per-unit costs on inventory that flowed through in Q3. Freight charges rose, lenses made in the U.S. and sold into China carried new tariff costs, and provisions for expiring inventory added further drag.
The prior-year Q3 included $25.9 million of previously deferred China revenue recognized at 100% gross margin, a one-time tailwind that makes the current quarter look worse in both revenue growth and margin terms than the underlying business trajectory suggests. Excluding that deferred recognition, net sales rose 21% year over year.
Sponsored
STAAR has moved all China-bound implantable lens production to its Switzerland facility to remove tariff exposure going forward. Management guided for gross margin relief beginning in Q4, though unit costs are expected to remain elevated through year-end as Q2-produced inventory continues to sell through, with further improvement anticipated in 2027. CEO Warren Foust said the company has begun the clinical trial process for two next-generation presbyopia products, with first-in-human enrollment expected in the coming months, pending remaining regulatory clearances.
The balance sheet gives STAAR room to absorb the near-term pressure, with $206.4 million in cash and no debt as of the quarter's end. The board authorized a share repurchase program in September 2026, and the quarter generated positive free cash flow. Management pointed to record nine-month results as a foundation for delivering strong full-year 2026 GAAP net income.
Mentioned: STAA